None of the TGF-β inhibitors evaluated in clinical trials was approved for cancer treatment because TGF-β is essential for several normal physiological processes in the human body, such as the gene deletion of TGF-β1, autoimmunity, abundant T cell proliferation and activation, and Th1 differentiation. The gene discussed is TGFB1; the disease is cancer.